MELD-Na scores higher at 30-day readmission for decompensated cirrhosis during pandemic

CHICAGO — Patients readmitted to the hospital within 30 days for decompensated cirrhosis during the COVID-19 pandemic had fewer comorbidities but increased MELD-Na scores, according to data at Digestive Disease Week.“Patients with decompensated cirrhosis have a high rate of hospital readmission and mortality,” Michelle Y. Shi, MD, a board-certified internist at the Donald and Barbara…

Tennessee E. coli outbreak linked to raw milk from multistate cow-share

An outbreak of Shiga toxin-producing Escherichia coli in Tennessee was caused by raw milk consumption among members of a cow-share, according to a study.Two 10-month-old infants were hospitalized in August 2022 with confirmed Shiga toxin-producing E. coli, with one of the two developing hemolytic uremic syndrome (HUS) linked to raw milk distributed as part of…

Early palliative care ‘did not show a benefit’ for patients undergoing cancer surgery

Palliative care specialist services provided around the time of cancer surgery with curative intent failed to significantly improve patient outcomes, results of a randomized study showed.The findings, published in JAMA Surgery, revealed that early specialist palliative care for this group of patients, who underwent major abdominal operations to cure or control their cancer, did not…

Elevated BMI in adulthood may increase GI cancer risk, regardless of aspirin use

Overweight and obese BMI during adulthood appeared associated with increased risk for colorectal cancer and noncolorectal gastrointestinal cancers, according to study results published in JAMA Network Open.Frequent aspirin use failed to modify the association.The findings of the secondary analysis of the NCI Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial prompt further exploration into…

Q&A: Too much CBD could be bad for the liver

A recent systematic review and meta-analysis revealed that moderate to high doses of cannabidiol were associated with liver enzyme elevation and drug-induced liver injury, meeting the criteria of common adverse drug events.Specifically, Lindsay Lo, MSc, BSc, an MPH student at the University of Toronto’s Dalla Lana School of Public Health, and colleagues reported in the…

VIDEO: No change in concomitant medications after Rebyota for recurrent C. difficile, IBD

CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.Allegretti presented data at Digestive Disease Week on safety outcomes and concomitant medication changes after treatment with Rebyota (fecal microbiota, live-jslm/RBX2660, Ferring Pharmaceuticals) —…